Business UpdateJun 15, 2026, 04:56 PM
Vistagen Fasedienol Phase 3 SAD Trial Misses Endpoint; Pipeline Progresses
AI Summary
Vistagen Therapeutics reported mixed results for its lead product candidate, fasedienol, in its Phase 3 PALISADE-3 trial for social anxiety disorder, which did not meet its primary endpoint. This follows a previous miss in PALISADE-1 but a success in PALISADE-2. The company expects topline results for PALISADE-4 in Q2 2026 and the Repeat Dose Study in Q3 2026, while preliminary open-label extension data showed favorable safety and exploratory efficacy. Additionally, Vistagen received a "Study May Proceed" letter from the FDA for U.S. Phase 2 development of refisolone for menopausal hot flashes and continues to advance other pipeline candidates like itruvone, PH15, and PH284.
Key Highlights
- Vistagen's fasedienol Phase 3 PALISADE-3 trial for social anxiety disorder did not meet its primary endpoint.
- Topline results for fasedienol's Phase 3 PALISADE-4 trial are expected in Q2 2026.
- Topline results for fasedienol's Repeat Dose Study are expected in Q3 2026.
- Vistagen met ICH E1 minimum patient exposures for fasedienol as of May 31, 2026, with over 1,500 subjects.
- FDA granted a "Study May Proceed" letter for refisolone's U.S. IND in April 2026 for menopausal hot flashes.
- FDA granted fast track designation for itruvone in MDD and AV-101 in neuropathic pain and adjunctive MDD.
- Vistagen is assessing third-party collaboration for further development and commercialization of AV-101.
- New patent applications for PH15 and nasal spray devices have nominal expiration dates in 2044 and 2045.
Price Impact
More from VTGN